Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHFree Report) in a research report report published on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Down 25.5 %

Shares of BLPH opened at $0.01 on Friday. The stock has a market capitalization of $146,796.00, a P/E ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.02. The firm has a fifty day simple moving average of $0.03 and a two-hundred day simple moving average of $0.03.

Bellerophon Therapeutics Dividend Announcement

The firm also recently declared a dividend, which was paid on Wednesday, December 18th. Investors of record on Friday, December 20th were issued a dividend of $0.019 per share. The ex-dividend date of this dividend was Thursday, December 19th. This represents a yield of 117.8%.

Bellerophon Therapeutics Company Profile

(Get Free Report)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Recommended Stories

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.